MindBio Therapeutics Corp. (CSE:MBIO)

Canada flag Canada · Delayed Price · Currency is CAD
2.490
-0.210 (-7.78%)
At close: Dec 5, 2025
-68.88%
Market Cap 5.52M
Revenue (ttm) n/a
Net Income (ttm) -3.66M
Shares Out 2.04M
EPS (ttm) -5.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 936
Average Volume 3,352
Open 2.250
Previous Close 2.700
Day's Range 2.250 - 2.490
52-Week Range 0.500 - 12.000
Beta -0.78
RSI 55.31
Earnings Date Oct 29, 2025

About MindBio Therapeutics

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for de... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements

News

There is no news available yet.